Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MindBio Therapeutics Corp C.MBIO

Healthcare Biotechnology
MindBio Therapeutics Corp. is a biotech/biopharma company. It creates novel and emerging treatments for mental health conditions and is conducting take-home Microdosing (MB22001) human clinical trials. MB22001 is its lead candidate drug, a titratable form of Lysergic Acid Diethylamide designed for take-home microdosing. It is focused on microdosing of psychedelic medicines and is advancing its drug and technology protocols through clinical trials. It develops a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase 1 clinical trials in 80 healthy participants and has completed a Phase 2a clinical trial in patients with Major Depressive Disorder. The underway are two Phase 2B trials, one in cancer patients experiencing existential distress and another in patients with Major Depressive Disorder. It invests in research that forms the basis for developing novel and clinically proven treatments.


CSE:MBIO - Post by User

MindBio Therapeutics Corp
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(8)
•••
Post by RocketRed777on May 14, 2024 9:53am
55 Views
Post# 36038544

ENVERIC BIOSCIENCES SIGNS $66.5 MILLION

ENVERIC BIOSCIENCES SIGNS $66.5 MILLION

 

Mindbio signs term sheet for Enveric psilocin prodrugs

2024-05-14 09:35 ET - News Release
Shares issued 135,047,305
MBIO Close 2024-05-13 C$ 0.055

Mr. Justin Hanka reports

ENVERIC BIOSCIENCES SIGNS $66.5 MILLION NON-BINDING TERM SHEET WITH MINDBIO THERAPEUTICS TO OUT-LICENSE NOVEL PSILOCIN PRODRUG CANDIDATE FOR MENTAL HEALTH DISORDERS


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities